It has prompted reconsideration of reason why ADCs may not be suitable for use in patients with gliomas, including the relatively high toxicity when targeting the EGFR family with certain payloads, and the concern that these drugs are unable to penetrate the blood brain barrier to reach glioma tumour cells. This evidence concerns the gene EGFR and neoplasm.